The Effect of the Awareness Development Program on Suicide Prevention for Oncology Nurses (RCT)

February 20, 2024 updated by: Sevda Ozturk

The Effect of the Awareness Development Program on Suicide Prevention for Oncology Nurses on the Levels of Suicide Knowledge, Stigma and Perception of Efficacy

The goal of this clinical trial is to investigate the effect of the Awareness Development Programme on Suicide Prevention for Oncology Nurses on the levels of knowledge, stigma and perception of efficacy towards suicide in oncology nurses. The main questions it aims to answer are:

  1. At the end of the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to nurses working in the field of oncology and at the end of the 3-month follow-up, is there a difference between the knowledge levels of nurses about suicide according to the pre-programme and control group?
  2. At the end of the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to nurses working in the field of oncology and at the end of the 3-month follow-up, is there a difference between the perception of efficacy levels of nurses regarding suicide according to the pre-programme and control group.
  3. At the end of the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to nurses working in the field of oncology and at the end of the 3-month follow-up, is there a difference between the stigma levels of nurses towards suicide according to the pre-programme and control group.
  4. Is there a significant relationship between the levels of knowledge about suicide, perception of efficacy regarding suicide, and stigma towards suicide in the pre-test and post-test measurements of the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to nurses working in the field of oncology.
  5. Is there a significant relationship between the levels of knowledge about suicide, perception of efficacy regarding suicide, and stigma towards suicide in the pre-test-follow-up test measurements of the Awareness Development Programme on Suicide Prevention for Oncology Nurses applied to nurses working in the field of oncology.

Participants will participate the Awareness Development Programme on Suicide Prevention for Oncology Nurses. Oncology Nurses are expected to complete the pre-test, post-test and follow-up tests.

Researchers will compare control group to see if effect of "the Awareness Development Programme on Suicide Prevention"

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This research is an intervention study with a pre-test, post-test, follow-up design and control group, which was conducted to examine the effect of the "Awareness Development Program on Suicide Prevention for Oncology Nurses" on oncology nurses' knowledge, stigma and effectiveness perception levels regarding managing suicide risk.

Study Type

Interventional

Enrollment (Actual)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Ankara, Turkey, 06100
        • Hacettepe University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • To be willing to participate in the study,
  • Being a nurse working in oncology inpatient clinics (medical oncology, medical oncology, gastroenterology oncology, nephrology oncology, urooncology, gynaecological oncology, haematological oncology inpatient clinics), Bone Marrow Transplantation (BMT) unit, outpatient chemotherapy unit and oncology outpatient clinic,
  • To know how to use a smart mobile phone or computer.

Exclusion Criteria:

  • To have training other than undergraduate education for suicide prevention,
  • To care for paediatric oncology patients,
  • To have worked in a psychiatric clinic or to have postgraduate education in the field of psychiatric nursing.
  • Failure to attend two out of three sessions during the training programme,
  • Failure to demonstrate the motor skills to participate in online training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group
"Awareness Development Program on Suicide Prevention for Oncology Nurses" was applied to the nurses in the experimental group.
Other: "Awareness Development Program on Suicide Prevention for Oncology Nurses"

While developing the "Awareness Development Programme on Suicide Prevention for Oncology Nurses" applied to the nurses in the experimental group, literature information on suicide risk management and suicide prevention in oncology was included in the study content by the researchers. "Awareness Development Programme on Suicide Prevention for Oncology Nurses" includes 3 sessions and the titles of the programme are as follows:

Session 1: Introduction to Understanding Suicide "Awareness and Development" Session 2: Assessing Suicide Risk Session 3: Management of Suicide Risk "Communication and Referral" The programme was submitted to the opinions of 5 experts before starting the study and the programme was finalised after the feedbacks.
No Intervention: Control Group
No programme was applied to the control group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the Literacy of Suicide Scale
Time Frame: Pretests were applied before the sessions. Intervention sessions of three sessions were implemented 5-8 days apart. Post-tests were administered as soon as the third session was completed. Follow-up tests were conducted 90 days after the post-tests.
A minimum score of 0 and a maximum total score of 27 can be obtained from the scale. The scale does not have any cut-off point. The higher the score obtained from the scale, the higher the level of knowledge about suicide.
Pretests were applied before the sessions. Intervention sessions of three sessions were implemented 5-8 days apart. Post-tests were administered as soon as the third session was completed. Follow-up tests were conducted 90 days after the post-tests.
Efficacy Perception Scale For Suicide Risk Management
Time Frame: Pretests were applied before the sessions. Intervention sessions of three sessions were implemented 5-8 days apart. Post-tests were administered as soon as the third session was completed. Follow-up tests were conducted 90 days after the post-tests.
This scale consists of 26 items. The lowest score that can be obtained from this scale is 26 and the highest score is 130, and the scale has no cut-off point. An increase in the score obtained from the scale indicates that nurses' self-perception is becoming more positive in relation to their knowledge and skills in the recognition and management of suicide risk.
Pretests were applied before the sessions. Intervention sessions of three sessions were implemented 5-8 days apart. Post-tests were administered as soon as the third session was completed. Follow-up tests were conducted 90 days after the post-tests.
The Stigma of Suicide Scale
Time Frame: Pretests were applied before the sessions. Intervention sessions of three sessions were implemented 5-8 days apart. Post-tests were administered as soon as the third session was completed. Follow-up tests were conducted 90 days after the post-tests.
There are 55 items in total in the scale. The scale has three subscales: "stigma", "isolation/depression" and "glorification/normalization". Total score is not calculated in the scale. High scores from the "stigma" sub-dimension of the scale indicate high stigma towards suicide. High scores from the "isolation/depression" sub-dimension of the scale indicate that suicide is more associated with depression and isolation, while high scores from the "normalization" sub-dimension indicate that individuals normalize suicide rather than stigmatizing people who commit suicide.
Pretests were applied before the sessions. Intervention sessions of three sessions were implemented 5-8 days apart. Post-tests were administered as soon as the third session was completed. Follow-up tests were conducted 90 days after the post-tests.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sevda Ozturk

Investigators

  • Principal Investigator: Duygu Hiçdurmaz, Prof., Hacettepe University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 25, 2023

Primary Completion (Actual)

November 2, 2023

Study Completion (Actual)

November 2, 2023

Study Registration Dates

First Submitted

February 12, 2024

First Submitted That Met QC Criteria

February 20, 2024

First Posted (Actual)

February 28, 2024

Study Record Updates

Last Update Posted (Actual)

February 28, 2024

Last Update Submitted That Met QC Criteria

February 20, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1292

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicide Prevention

Clinical Trials on "Awareness Development Program on Suicide Prevention for Oncology Nurses"

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe